Arbutus Biopharma to Present Promising Imdusiran and AB-101 Data for Chronic Hepatitis B at EASL Congress 2025
• Arbutus Biopharma will present five abstracts at EASL Congress 2025, showcasing data on imdusiran and AB-101 for chronic hepatitis B treatment, including one late-breaker abstract.
• Clinical data reveals that imdusiran, when combined with pegylated interferon and nucleos(t)ide analogue therapy, achieved meaningful functional cure rates in chronic hepatitis B patients through targeted RNAi action.
• AB-101, an oral PD-L1 inhibitor, demonstrated promising safety profiles and dose-responsive receptor occupancy in early trials, potentially offering controlled immune checkpoint blockade with fewer systemic side effects than antibody therapies.
Arbutus Biopharma Advances cHBV Program with Imdusiran Phase 2b Trial Initiation Planned for 2025
• Arbutus Biopharma plans to initiate a Phase 2b clinical trial of imdusiran, combined with interferon and nucleos(t)ide analogue therapy, in the first half of 2025 for cHBV.
• The planned Phase 2b trial will enroll approximately 170 HBeAg-negative cHBV patients with baseline HBsAg levels ≤1000 IU/mL, pending regulatory approval.
• Arbutus's oral PD-L1 inhibitor, AB-101, is currently in Phase 1a/1b trials, with data from the 10 mg cohort expected in the first half of 2025.
• The company's financial update indicates a strong cash position, with resources sufficient to fund operations through Q1 2028, including the imdusiran Phase 2b trial.
Arbutus Biopharma's Imdusiran Shows Promise in Hepatitis B Functional Cure
• Arbutus Biopharma's IM-PROVE I Phase 2a trial reveals potential advancements in chronic hepatitis B (cHBV) treatment using imdusiran.
• The trial achieved a 25% functional cure rate overall, with 50% in HBeAg-negative patients with low baseline HBsAg levels.
• Combination therapy of imdusiran, pegylated interferon alfa-2α, and nucleos(t)ide analogue was well-tolerated, with no serious adverse events.
• Arbutus plans to advance imdusiran into a Phase 2b clinical trial, aiming for more effective cHBV treatment solutions.
Imdusiran, VTP-300, and Nivolumab Combination Shows Promise in Chronic Hepatitis B
• A Phase 2a trial shows that imdusiran, VTP-300, and low-dose nivolumab led to significantly greater HBsAg declines in chronic hepatitis B patients.
• 23% of participants receiving the combination therapy achieved HBsAg loss by Week 48, indicating a potential path to functional cure.
• The triple combination was generally well-tolerated, with no immune-related adverse events reported during the study period.
• These findings support the strategy of combining surface antigen reduction with immune reawakening in HBV treatment.
© Copyright 2025. All Rights Reserved by MedPath